
CORRESPONDENCE

Open Access





Valliappan Muthu and Ritesh Agarwal*

Keywords: Asthma, Cystic fibrosis, Abpm, Allergic bronchopulmonary mycosis, Aspergillosis, Aspergillus

We read with interest the case presented by Sasada et al., describing the occurrence of aspergillosis in a patient who underwent bronchial thermoplasty (BT) [1]. The isolation of Aspergillus fumigatus, the presence of elevated serum total IgE, and possible eosinophilic inflammation (high FeNO) suggest allergic sensitization to *A. fumigatus*. However, the diagnosis remains unproven as specific IgE or skin test against A. fumigatus was not performed in the index case. The authors mention that there was a remarkable improvement after BT. With only two sessions of BT being completed, the observed improvement is likely the effect of itraconazole therapy. Itraconazole offers excellent results in patients with severe asthma with fungal sensitization (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) [2, 3]. The absence of bronchiectasis on computed tomography does not rule out ABPA and therefore, immunological investigations are required [4]. The prevalence of *Aspergillus* sensitization is about 28% in asthmatics and maybe as high as 50% in those with severe asthma [5, 6].

There is a significant burden of fungal allergy in Japan. In a recent Japanese study of 124 subjects with SAFS, 29% had allergic sensitization to at least one fungus, and sensitization to *A.fumigatus* was seen in 11% [7]. With such a high prevalence of fungal allergy in Japan, it would be reasonable to exclude SAFS or ABPA before BT. BT is a valuable addition in severe asthma management, especially

for those who are not candidates for oral glucocorticoids or biologic therapy. Nevertheless, a thorough evaluation of coexisting conditions or complications is an indispensable component while evaluating severe asthma [8, 9]. Further, the trials evaluating BT or biologics in asthma have not included subjects with SAFS or ABPA. Hence, extrapolating the results beyond the trial population may be problematic. Thus, the index case should serve as a reminder to systematically evaluate severe asthma before contemplating treatment with newer modalities such as BT.

Abbreviations

ABPA: Allergic bronchopulmonary aspergillosis; BT: Bronchial thermoplasty; SAFS: Severe asthma with fungal sensitization.

Acknowledgements

None.

Authors' contributions

VM—draft and revision of the manuscript. RA—conceptualized, drafted and revised the manuscript. Both authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

*Correspondence: agarwal.ritesh@outlook.in Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Consent for publication

Not applicable.

Competing Interests

The authors declare that they have no competing interests.

Received: 18 December 2020 Accepted: 11 May 2021 Published online: 18 May 2021

References

- Sasada S, Ohmura K, Oguri T, Fujimoto Y, Murata S, Tsuchiya Y, et al. A
 case report of aspergillosis accompanied by saccular bronchodilation
 after bronchial thermoplasty in a 19-year-old woman. Bmc Pulm Med.
 2020;20(1):312
- Denning DW, O'droscoll BR, Powell G, Chew F, Atherton GT, Vyas A, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the fungal asthma sensitization trial (fast) study. Am J Respir Crit Care Med. 2009;179(1):11–8.
- Agarwal R, Dhooria S, Singh Sehgal I, Aggarwal AN, Garg M, Saikia B, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018;153(3):656–64.

- Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol. 2012;4(4):141–50.
- Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009:13(8):936–44.
- Agarwal R, Nath A, Aggarwal AN, Gupta D, Chakrabarti A. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India. Mycoses. 2010;53(2):138–43.
- Masaki K, Fukunaga K, Matsusaka M, Kabata H, Tanosaki T, Mochimaru T, et al. Characteristics of severe asthma with fungal sensitization. Ann Allergy Asthma Immunol. 2017;119(3):253–7.
- Majellano EC, Clark VI, Winter NA, Gibson PG, Mcdonald VM. Approaches to the assessment of severe asthma: barriers and strategies. J Asthma Allergy. 2019;12:235–51.
- Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Med Mycol. 2011;49(Suppl 1):S150–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

